Cell therapy boost: Hitachi Chemical expands CDMO site in New Jersey, US

By Flora Southey

- Last updated on GMT


Related tags United states

Hitachi Chemical is expanding manufacturing and cleanroom capacity at its cell therapy-focused CDMO site in Allendale, New Jersey, US.

The expansion will see Hitachi Chemical Advanced Therapeutics Solutions (HCATS) add 49,700 sq. ft. to its contract development and manufacturing organisation’s (CDMO) branch, PCT.

The site will house manufacturing development labs, quality control and microbiology labs, additional Grade B/ISO 7 cleanrooms, warehousing and office space.

Validation for the facility is planned before the end of 2018.

The firm said it expects the expansion to attract new business to PCT.

“HCATS anticipates that the increase in demand for cell therapy development and manufacturing services will result in substantial growth of the company’s employee base in the company year,” ​said the company.

Pearl Court & Yokohama upgrades

The firm also announced plans to upgrade its Pearl Court site in Allendale, and said its regenerative cell-focused CDMO site in Yokohama, Japan, which is under construction, will be validated by April, 2018.

Hitachi Chemical Co. America – the US off-shoot of Japan-based Hitachi Chemical – purchased​ PTC from majority shareholder Caladrius Biosciences earlier this year.

Related news

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers

Follow us


View more